Delving into the Latest Updates on 68Ga-FAPI-04 with Synapse

As a novel radiotracer targeting fibroblast activation protein (FAP), 68Ga-DOTA-NI-FAPI04 is a novel agent incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a FAP-targeting. In this study, we observed the diagnostic performance of 68Ga-DOTA-NI-FAPI04 PET/CT in patients with different types of cancer, and compared its imaging results with those of 68Ga-FAPI or 18F-FDG PET/CT.

Start Date01 Apr 2024

Sponsor / Collaborator

First Affiliated Hospital Of Fujian Medical University

NCT06455735 / RecruitingEarly Phase 1IIT

68Ga-JH04 PET/CT in Patients With Various Types of Cancer

As a novel radiotracer targeting fibroblast activation protein (FAP), 68Ga-JH04 is promising as an excellent imaging agent for various cancers. In this study, we observed the diagnostic performance of 68Ga-JH04 PET/CT in patients with different types of cancer, and compared its imaging results with those of 68Ga-FAPI or 18F-FDG PET/CT.

Start Date01 Mar 2024

Sponsor / Collaborator

First Affiliated Hospital Of Fujian Medical University

NCT05999227 / RecruitingNot ApplicableIIT

68Ga-FAPI-04 PET Imaging in Early Response Evaluation of Rectal Cancer Patients Treated With Immunotherapy: A Single-center Clinical Study

This study is a prospective monocentric study aimed to explore the value of 68Ga-FAPI-04 PET imaging in early response evaluation of rectal cancer patients treated with immunotherapy. Patients with histopathologically confirmed diagnosis of rectal cancer will be recruited and undergo 68Ga-FAPI-04 and 18F-FDG PET imaging before treatment and after short-course radiotherapy and two cycles of neoadjuvant chemotherapy plus immunotherapy. The two imaging intervals will be completed two days apart. The efficacy of 68Ga-FAPI-04 in early response evaluation will be compared with the general imaging agent 18F-FDG. The general information, clinical data, mpMRI data, 68Ga-FAPI-04 and 18F-FDG PET imaging results and other imaging data of the patients will be collected. The histopathology of the biopsy or surgical specimen after 2 cycles of therapy and follow-up data will be taken as evaluation references. This study plans to set the sample size as 20 cases

Start Date20 Jun 2023

Sponsor / Collaborator

Wuhan Xiehe Hospital Tower

100 Clinical Results associated with 68Ga-FAPI-04

Login to view more data

100 Translational Medicine associated with 68Ga-FAPI-04

Login to view more data

100 Patents (Medical) associated with 68Ga-FAPI-04

Login to view more data

77

Literatures (Medical) associated with 68Ga-FAPI-04

01 Jan 2025·CLINICAL NUCLEAR MEDICINE

68Ga-FAPI-04 PET/CT Imaging in a Patient With Psoriatic Arthritis

Article

Author: Yang, Lixiang ; Tian, Rong ; Jiang, Lisha ; Li, Qianrui ; Zhang, Zitong

Abstract:

We described the findings of 68Ga-FAPI-04 PET/CT of psoriatic arthritis in a 56-year-old man. Intense FAPI uptake was observed alongside the spine and in the joints of bilateral feet and the right hip. 68Ga-FAPI PET/CT is potentially valuable for the evaluation of join involvement and disease activity in patients with psoriasis.

01 Oct 2024·CLINICAL NUCLEAR MEDICINE

Comparison of 68Ga-FAPI-04 and 18F-FDG PET/CT in Fumarate Hydratase-Deficient Renal Cell Carcinoma

Article

Author: Liu, Haoyang ; Dai, Hongyuan ; Huang, Rui ; Su, Minggang ; Qi, Mengfang ; Zeng, Hao ; Huang, Shuhui

Purpose:

Fumarate hydratase-deficient renal cell cancer (FHRCC) is a rare and aggressive form of renal cell carcinoma. The diagnostic value of 68Ga-FAPI PET/CT for FHRCC remains unexplored. Therefore, we compared the potential value of 68Ga-FAPI-04 and 18F-FDG PET/CT in FHRCC.

Patients and Methods:

Patients with FHRCC underwent 68Ga-FAPI-04 and 18F-FDG PET/CT from May 2022 to December 2023. The SUVmax and tumor-to-liver ratio (TLR) of both tracers were compared using the Wilcoxon signed rank test.

Results:

Eleven patients with 83 lesions were enrolled. The rate of 18F-FDG PET/CT in detecting lesions was higher than that of 68Ga-FAPI-04 PET/CT: primary tumors: 75.0% (6/8) versus 50.0% (4/8); lymph nodes: 94.9% (37/39) versus 89.7% (35/39); and bone lesions: 100.0% (21/21) versus 90.5% (19/21). The median SUVmax of primary and metastatic lesions on 18F-FDG PET/CT was comparable to 68Ga-FAPI-04 PET/CT in semiquantitative analysis (primary lesions: 13.86 vs 16.35, P = 1.000; lymph nodes: 10.04 vs 9.33, P = 0.517; bone lesions: 13.49 vs 9.84, P = 0.107; visceral lesions: 8.54 vs 4.20, P = 0.056). However, the median TLRs of primary and metastatic lesions on 68Ga-FAPI-04 PET/CT were higher than that of 18F-FDG PET/CT (primary lesions: 30.44 vs 5.41, P = 0.010; lymph nodes: 17.71 vs 3.95, P = 0.000; bone lesions: 15.94 vs 5.21, P = 0.000; visceral lesions: 9.26 vs 3.44, P = 0.003).

Conclusions:

18F-FDG PET/CT detected more primary and metastatic FHRCC lesions than 68Ga-FAPI-04 PET/CT. However, the higher TLR in FHRCC on 68Ga-FAPI-04 PET/CT may indicate therapeutic potential in targeting fibroblast activation protein in FHRCC.

01 Oct 2024·CLINICAL NUCLEAR MEDICINE

The Contribution of 68Ga-FAPI-04 PET/CT to Staging and Prognosis in Gastric Cancer

Article

Author: Erol Fenercioğlu, Özge ; Şahin, Rahime ; Alçin, Göksel ; Ergül, Nurhan ; Arslan, Esra ; Beyhan, Ediz ; Çermik, Tevfik Fikret ; Aksoy, Tamer

Aim:

This study aimed to compare the diagnostic capabilities of 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT imaging in staging gastric carcinoma, exploring the impact of 68Ga-FAPI-04 PET/CT on treatment planning and its prognostic significance.

Methods:

The research included 31 patients undergoing staging for gastric cancer, who received both 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT scans. We compared the SUVmax and SUVmean of the primary tumor and lymph nodes, the count of organ metastases, tumor-to-background ratios, and overall staging accuracy. Additionally, the study evaluated radiological progression-free survival and overall survival rates.

Results:

The 68Ga-FAPI-04 PET/CT demonstrated superior efficacy in identifying the primary tumor compared with 18F-FDG PET/CT, particularly in cases of poorly cohesive, signet-ring cell, and mucinous subtypes, with detection rates of 96.7% versus 77.4% (P = 0.006 and P = 0.008, respectively). Analysis of lymph nodes showed a significantly higher detection of positive nodes with 68Ga-FAPI-04 (P = 0.026), although no significant differences were observed in SUVmax and tumor-to-background ratio on a patient basis (P > 0.05). SUVmax and tumor-to-background ratios for peritoneal involvement were notably higher with 68Ga-FAPI-04 PET/CT compared with 18F-FDG PET/CT (P = 0.04 for both). No significant differences were found in the detection of organ metastases and disease stage between the 2 imaging modalities (P > 0.05). Primary tumor uptake did not significantly impact radiological progression-free survival or overall survival in either modality.

Conclusions:

68Ga-FAPI-04 PET/CT imaging surpasses 18F-FDG PET/CT in detecting the primary tumor, especially in poorly cohesive and signet-ring cell gastric cancer types, and offers improved accuracy in disease staging. This indicates its potential to enhance treatment management and prognostic assessment in gastric cancer patients.

100 Deals associated with 68Ga-FAPI-04

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Carcinoma	Phase 1	CN	First Affiliated Hospital Of Fujian Medical University	01 Apr 2024
Fibrosis, Liver	Phase 1	CN	First Affiliated Hospital Of Fujian Medical University	01 Sep 2020
Breast Cancer	Preclinical	DE	University Hospital Heidelberg	06 Apr 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EANM2022	Not Applicable	Cardiovascular Diseases Fibroblast Activation Protein(FAP)	-	68 Ga-FAPI-04 (Case 1: 66 years old male with colangiocarcinoma)	jewxuovtaw(xccgfeaojk) = bvwtccxyyq kfruckklvs (pbgiegzozu )	-	22 Sep 2022
				68 Ga-FAPI-04 (Case 2: 69 years old male with smoking and peripheral artery disease history)	jewxuovtaw(xccgfeaojk) = odmdyjighe kfruckklvs (pbgiegzozu )
SNMMI2022	Not Applicable	Gastrointestinal Neoplasms	-	68Ga-FAPI-04 PET/CT	fpytdmxmde(bpvknoeiwl) = owxnqjjefz qoulonydpb (snpzlxgzub )	-	08 Aug 2022
				68Ga-FAPI-0418F-FDGPI-04 (18F-FDG PET/CT)	fpytdmxmde(bpvknoeiwl) = owadcdznos qoulonydpb (snpzlxgzub )
EULAR2021	Not Applicable	Interstitial lung disease due to systemic disease Fibroblast Activation Protein (FAP)	21	68GA-FAPI-04 (SSc-ILD patients)	mkprdpqwio(ifsmtutoaa) = plgssgpnjm ljdfclypqg (mksgerkyly ) View more	-	02 Jun 2021